In brief, for ECG outcomes, there was no difference between group of patients on SGLT2 inhibitors and group of patients on non-SGLT2 inhibitors in terms of PR intervals, QT prolongations, new onset ST-T changes, new onset CRBBB or CLBBB, or ventricular arrhythmia. Here, SLC5A2 is linked to Ventricular arrhythmia.